Phaseline

Targets › CD40LG

CD40LG (CD40 ligand): drug programs, companies and trials

5 programs from 5 companies in 9 trials: 4 Phase 1, 3 Phase 3, 2 Phase 2; Immunology, Oncology, Genitourinary; next expected readout Dec 2026.

Cytokine that acts as a ligand to CD40/TNFRSF5. Costimulates T-cell proliferation and cytokine production. (UniProt, P29965)

Open in Phaseline: the race on CD40LG, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AmgenDazodalibep
CD40 ligand antagonist
CD40LGPhase 3Sjögren's Syndrome (SS); Sjögren's Syndrome; Lupus NephritisDec 2026
UCB Biopharma SRLdapirolizumab pegol
CD40 ligand inhibitor
CD40LGPhase 3Systemic Lupus ErythematosusMay 2028
AbbVieRavagalimab
CD40 ligand antagonist
CD40LGPhase 2Rheumatoid ArthritisFeb 2027
Eledon PharmaceuticalsTegoprubart (AT-1501)
CD40 ligand inhibitor
CD40LGPhase 1Prevention of Rejection in Kidney Transplant; Type 1 Diabetes Mellitus; Diabete Type 1Jan 2027
H. Lee Moffitt Cancer Center and Research InstituteCD40L-augmented TIL
Tumor-infiltrating lymphocytes engineered with CD40L co-stimulatory molecule for enhanced
CD40LGPhase 1MelanomaMay 2029

Conditions

Systemic Lupus Erythematosus (1) Melanoma (1) Rheumatoid Arthritis (1) Prevention of Rejection in Kidney Transplant (1) Type 1 Diabetes Mellitus (1) Diabete Type 1 (1) Sjögren's Syndrome (SS) (1) Sjögren's Syndrome (1) Lupus Nephritis (1)

Modalities

small molecule (3), mixed (1), antibody (1)

Companies

UCB Biopharma SRL (1) H. Lee Moffitt Cancer Center and Research Institute (1) AbbVie (1) Eledon Pharmaceuticals (1) Amgen (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.